SCHEMBL22609293

SCHEMBL22609293

Fc1ccc(Cc2ccnnc2)cc1

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LOXL2 Q9Y4K0 2/20 0.48
CYP11B1 P15538 6/20 0.40
CYP11B2 P19099 6/20 0.40
CYP17A1 P05093 4/20 0.40
CYP3A4 P08684 3/20 0.40
IDO1 P14902 2/20 0.38
HSD17B10 Q99714 1/20 0.37
TAAR1 Q96RJ0 2/20 0.36
HTR2C P28335 2/20 0.36
HTR2B P41595 1/20 0.36
ALDH1A1 P00352 3/20 0.36
MAPK1 P28482 1/20 0.36
HTT P42858 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
KDM4E B2RXH2 1/20 0.36
HPGD P15428 1/20 0.36
CYP19A1 P11511 3/20 0.35
AGXT P21549 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1772471 0.79 LOXL2 (0.48) LOXL2CYP11B1CYP11B2CYP17A1CYP3A4
SCHEMBL1985814 0.78 CALM1 (0.55) LOXL2CYP11B1CYP11B2HSD17B10TAAR1
SCHEMBL7482733 0.78 CYP17A1 (0.58) CYP11B1CYP11B2CYP17A1CYP3A4ALDH1A1
SCHEMBL16561361 0.76 IDO1 (0.58) LOXL2CYP3A4IDO1TAAR1ALDH1A1
SCHEMBL1468357 0.76 IDO1 (0.58) LOXL2CYP3A4IDO1TAAR1ALDH1A1
SCHEMBL28302304 0.75 LTA4H (0.55) LOXL2CYP11B1CYP11B2CYP17A1IDO1
Hydrochloric Acid SCHEMBL7941845 0.74 IDO1 (0.55) LOXL2CYP3A4IDO1TAAR1ALDH1A1
SCHEMBL3758352 0.73 TBXAS1 (0.56) CYP11B1CYP11B2
SCHEMBL18770326 0.72 CYP17A1 (0.68) CYP11B1CYP11B2CYP17A1CYP3A4CYP19A1
SCHEMBL28566929 0.72 LOXL2 (0.41) LOXL2CYP3A4HSD17B10ALDH1A1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210171503-A1 GLYCOLATE OXIDASE INHIBITORS AND USE THEREOF ORFAN BIOTECH SL (ES) 2021-06-10 US disclosed
EP-3731840-A1 GLYCOLATE OXIDASE INHIBITORS AND USE THEREOF Orfan Biotech Inc. (US) 2020-11-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210171503-A1 GLYCOLATE OXIDASE INHIBITORS AND USE THEREOF PNPO, XDH, GLS LOXL2 227/4885CYP11B1 278/4885CYP11B2 339/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.